SI-BONE, INC. (SIBN) Spending and interest coverage
- R&D / revenue · 12 months: Value 8.44%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 11.33%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 8.44% | Research and development expense / revenue. Period ending 2026-06-30. $18.02M ÷ $213.60M × 100 ≈ 8.44% |
| Stock-based compensation / revenue · 12 months | 11.33% | Share-based compensation / revenue. Period ending 2026-06-30. $24.21M ÷ $213.60M × 100 ≈ 11.33% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 18.02M USD | Research and Development Expense |
| Revenue | 213.60M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 24.21M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -17.75M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.02M | $213.60M | $24.21M | $-17.75M | (m) | 8.44% | 11.33% | (m) | (m) |
| 2026-03-31 | $17.11M | $206.22M | $24.89M | $-19.94M | (m) | 8.29% | 12.07% | (m) | (m) |
| 2025-12-31 | $17.45M | $200.93M | $25.52M | $-22.33M | (m) | 8.68% | 12.70% | (m) | (m) |
| 2025-09-30 | $16.95M | $193.58M | $25.68M | $-25.36M | (m) | 8.76% | 13.27% | (m) | (m) |
| 2025-06-30 | $16.71M | $185.26M | $25.76M | $-27.61M | (m) | 9.02% | 13.91% | (m) | (m) |
| 2025-03-31 | $16.75M | $176.60M | $25.50M | $-30.68M | (m) | 9.48% | 14.44% | (m) | (m) |
| 2024-12-31 | $16.56M | $167.18M | $25.87M | $-35.25M | (m) | 9.91% | 15.47% | (m) | (m) |
| 2024-09-30 | $16.85M | $157.03M | $25.67M | $-42.26M | (m) | 10.73% | 16.35% | (m) | (m) |
| 2024-06-30 | $16.78M | $150.71M | $25.29M | $-45.80M | (m) | 11.13% | 16.78% | (m) | (m) |
| 2024-03-31 | $16.08M | $144.04M | $24.89M | $-47.68M | $3.50M | 11.16% | 17.28% | -13.60× | Reported |
| 2023-12-31 | $15.03M | $138.89M | $24.06M | $-46.93M | $3.46M | 10.82% | 17.32% | -13.56× | Reported |
| 2023-09-30 | $14.35M | $131.98M | $24.00M | $-45.72M | $3.45M | 10.87% | 18.19% | -13.24× | Reported |
| 2023-06-30 | $13.52M | $124.40M | $24.00M | $-48.12M | $3.33M | 10.87% | 19.29% | -14.47× | Reported |
| 2023-03-31 | $13.34M | $116.68M | $23.75M | $-54.03M | $3.10M | 11.43% | 20.35% | -17.45× | Reported |
| 2022-12-31 | $13.63M | $106.41M | $23.06M | $-59.61M | $2.82M | 12.81% | 21.67% | -21.15× | Reported |
| 2022-09-30 | $13.20M | $99.69M | $21.52M | $-62.25M | $2.51M | 13.24% | 21.59% | -24.84× | Reported |
| 2022-06-30 | $13.39M | $95.54M | $19.84M | $-61.88M | $4.41M | 14.02% | 20.76% | -14.03× | Reported |
| 2022-03-31 | $13.07M | $92.15M | $18.34M | $-56.96M | $4.86M | 14.18% | 19.91% | -11.72× | Reported |
| 2021-12-31 | $12.44M | $90.15M | $16.87M | $-51.67M | $5.37M | 13.80% | 18.71% | -9.63× | Reported |
| 2021-09-30 | $11.82M | $87.07M | $15.70M | $-45.61M | $5.88M | 13.57% | 18.03% | -7.75× | Reported |
| 2021-06-30 | $11.31M | $85.15M | $14.64M | $-41.09M | $4.33M | 13.28% | 17.19% | -9.50× | Reported |
| 2021-03-31 | $10.32M | $77.01M | $13.34M | $-38.26M | $5.93M | 13.41% | 17.32% | -6.45× | Reported |
| 2020-12-31 | $9.46M | $73.39M | $11.93M | $-38.57M | $6.10M | 12.89% | 16.25% | -6.32× | Reported |
| 2020-09-30 | $8.81M | $71.05M | $10.63M | $-39.18M | $6.26M | 12.40% | 14.95% | -6.26× | Reported |
| 2020-06-30 | $7.91M | $66.86M | $9.36M | $-41.09M | $6.40M | 11.82% | 13.99% | -6.42× | Reported |
| 2020-03-31 | $7.69M | $69.13M | $8.21M | $-39.09M | $4.95M | 11.12% | 11.88% | -7.90× | Reported |
| 2019-12-31 | $7.28M | $67.30M | $7.46M | $-36.00M | $4.95M | 10.82% | 11.09% | -7.27× | Reported |
| 2019-09-30 | $7.00M | $63.11M | $6.83M | $-31.82M | $4.99M | 11.10% | 10.82% | -6.38× | Reported |
| 2019-06-30 | $6.50M | $60.31M | $5.24M | $-24.29M | $5.03M | 10.78% | 8.69% | -4.83× | Reported |
| 2019-03-31 | $5.85M | $57.66M | $3.79M | $-17.85M | $5.06M | 10.15% | 6.57% | -3.52× | Reported |
| 2018-12-31 | $5.38M | $55.38M | $2.31M | $-11.96M | $5.11M | 9.71% | 4.17% | -2.34× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $5.51M | $47.98M | $1.44M | $-17.35M | $6.20M | 11.49% | 3.00% | -2.80× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |